Kayla McCarthy
Adult Health · Shiloh, ILNPI 1861902025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations.
Across 225 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$599
- AbbVie$559
- Novo Nordisk$426
- AstraZeneca$350
- Johnson & Johnson$318
- GSK$261
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,719100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $599 |
| AbbVie | 38 | $559 |
| Novo Nordisk | 26 | $426 |
| AstraZeneca | 15 | $350 |
| Johnson & Johnson | 23 | $318 |
| GSK | 13 | $261 |
| Boehringer Ingelheim | 13 | $193 |
| Sanofi-aventis U.S. LLC | 10 | $159 |
| Amarin Pharma, Inc. | 7 | $112 |
| Abbott | 5 | $92 |
| Pfizer | 5 | $90 |
| Bayer | 4 | $77 |
| Amgen | 4 | $76 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| Dexcom, Inc. | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Exact Sciences | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $39 |
| Astellas Pharma US Inc | 2 | $36 |
| Novartis | 2 | $28 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Cequr Corporation | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$116
How this compares
$3,719 in reported general payments places this provider in the 85th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $24,521 |
| FarxigaDapagliflozin Propanediol | 27 | $21,586 |
| JardianceEmpagliflozin | 23 | $20,742 |
| MounjaroTirzepatide | 17 | $18,019 |
| EliquisApixaban | 16 | $17,515 |
| OzempicSemaglutide | 13 | $16,450 |
| MyrbetriqMirabegron | 13 | $11,995 |
| GemtesaVibegron | 12 | $10,522 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $8,353 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,428 |
| Varenicline Tartrate | 11 | $2,911 |
| Duloxetine Hcl | 62 | $1,485 |
| Atorvastatin Calcium | 100 | $1,389 |
| Levothyroxine Sodium | 68 | $914 |
| Bupropion XlBupropion Hcl | 26 | $887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $261 | $32,87356 claims |
| AstraZenecaFarxiga | $350 | $21,58627 claims |
| Boehringer IngelheimJardiance | $193 | $20,74223 claims |
| Lilly USA, LLCMounjaro | $599 | $18,01917 claims |
| PfizerEliquis | $90 | $17,51516 claims |
| Novo NordiskOzempic | $426 | $16,45013 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $11,99513 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $64 | $10,52212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 553 adult health providers in Illinois.
Other adult health in Shiloh
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
- Eileen SchedelAurora$21K
- Julia BuesserGurnee$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.